The Ban Landed. Tennessee Shows What Happens Next.

Ben Taylor used to buy his kratom the way most people buy energy drinks: at a gas station counter, no questions, no ID for anything but cigarettes. Now he’s a recovery advocate at Cumberland Heights, a Nashville treatment center, describing what it felt like to stop. He told NewsChannel 5 it was sleeplessness, body aches, and a feeling like “your bones are coming out of your body.”

That’s not a metaphor treatment staff invented for effect. It’s what opioid withdrawal — the flu-like, bone-deep sickness your body produces when it’s built a physical need for a substance and then loses access to it — actually feels like, whether the substance came from a pharmacy, a street corner, or a rack by the register at a Marathon station.

Cutting off supply doesn’t cut off the dependency it created, and the six weeks since kratom and 7-OH bans landed across several states are proof: the people who needed the drug most are the ones the law forgot to plan for.

If you’ve been buying kratom extract shots or 7-OH tablets — sold under a wall of brand names, often shelved near tianeptine products marketed as Tianaa, Zaza, or Neptune’s Fix — to get through a workday, keep from getting sick, or wean off something worse, this is written for you as much as for the policy reporters covering it. You’re not a footnote in a scheduling order. You’re the reason this story is still unfolding.

The math nobody in the DEA hearing room had to sit with

Here’s the layman version of what actually happened, because the regulatory language obscures how blunt this was. “Schedule I” is the federal government’s top classification for drugs it considers to have no accepted medical use and a high potential for abuse — the same category as heroin. On August 26, 2026, the DEA placed three lab-modified relatives of 7-OH (a concentrated, potent compound derived from kratom leaf) into Schedule I on a temporary, emergency basis. A separate rule setting a legal potency threshold for 7-OH itself was still working through public comment as of mid-September. Tianeptine — the antidepressant-turned-”gas-station-heroin” sold in bottles up front at convenience stores — is even further behind: the DEA proposed Schedule I placement on July 8, but as of this writing no final rule has been issued.

None of that regulatory lag mattered to Tennessee. The state’s own 7-OH ban took effect July 1, ahead of any of it. And that’s the part the national conversation keeps missing: the federal action is still incomplete, but the on-the-ground supply shock already happened, state by state, months before Washington finished paperwork. Fifteen-plus states had banned tianeptine outright before the DEA even proposed a federal rule, according to the DEA’s own filing, following a May 2025 warning letter from then-FDA Commissioner Marty Makary. People with physical dependency didn’t wait for a Federal Register notice to lose their supply. They lost it the day their state legislature or governor decided to move first.

What “cut off” actually produces, six weeks in

At Cumberland Heights, Dr. Chapman Sledge told local reporters something that should stop anyone reading this cold: his facility is now seeing more people seeking treatment for 7-OH and kratom dependency than for fentanyl. The ratio being reported out of Tennessee treatment centers is roughly 4-to-1 — four kratom or 7-OH withdrawal admissions for every one fentanyl case.

Read that number the way it deserves to be read. It doesn’t mean kratom dependency is worse than fentanyl dependency — Sledge himself noted acute kratom withdrawal has a higher survival rate than acute fentanyl withdrawal. It means there was a population of dependent users large enough, and invisible enough, that nobody built treatment capacity for them until the supply vanished and they showed up at intake desks all at once. Some patients told staff they’re now hunting for kratom sold under euphemisms like “cat’s claw” to dodge the ban — which tells you something else important: demand didn’t evaporate when the product got harder to find. It went underground and got harder to dose safely, because nothing on a gray-market label tells you what’s actually in the bag.

It doesn’t mean kratom dependency is worse than fentanyl dependency — Sledge himself noted acute kratom withdrawal has a higher survival rate than acute fentanyl withdrawal.

Dr. Julie Craig, an addiction medicine physician, laid out the more dangerous version of that same dynamic in a KevinMD op-ed published this month. She described 7-OH withdrawal as arriving fast and mimicking the combined crash of stopping heroin and methamphetamine at once, and warned that dependent users cut off without a treatment bridge are the ones most likely to reach for fentanyl instead — a drug most of them have zero tolerance for, which is exactly the condition that turns a withdrawal crisis into an overdose death. Craig also predicted a tianeptine resurgence as people search for the nearest legal-adjacent substitute, since federal tianeptine scheduling still hasn’t cleared.

History already ran this experiment once

This isn’t a new mechanism, and pretending it is lets everyone off the hook for not seeing it coming. In 2010, Purdue Pharma reformulated OxyContin into a version that was far harder to crush and snort, aiming to choke off pill misuse. It worked, in the narrow sense: illicit use of that specific pill dropped fast. But hundreds of thousands of people already physically dependent on prescription opioids didn’t stop needing opioids just because their preferred pill got harder to abuse. Researchers tracking the years after the reformulation found heroin deaths climbed as displaced pill users found a cheaper, more available substitute waiting on the street — one with no dose printed on it and no quality control at all. Heroin’s later contamination with fentanyl turned that substitution crisis into the deadliest drug period in American history. The mechanism is simple and it doesn’t care what decade it’s in: take away the substance a dependent body needs, without simultaneously handing that person a treatment pathway, and the body will go find something. It rarely finds something safer.

The substance quietly riding along in the substitution

There’s a second compound moving through this story that deserves its own line, because it’s the one showing up in toxicology reports without anyone choosing it. Xylazine — an animal tranquilizer not approved for human use, which depresses breathing and heart rate and doesn’t respond to naloxone the way opioids do — has been the most common adulterant found in the fentanyl supply since 2023, according to tracking cited by the ATTC Network’s Opioid Response Network. Tennessee’s own state health department briefing has been tracking its climb in overdose deaths for two years running. As people displaced from kratom and 7-OH drift toward the illicit opioid market to manage withdrawal, they’re not just risking fentanyl they have no tolerance for — they’re risking a supply that’s frequently cut with a sedative their body has never encountered and that standard overdose-reversal drugs don’t fully touch.

What’s still standing

Here’s the thing the ban didn’t touch, and it matters more right now than any scheduling order: buprenorphine and naloxone — the medications that treat opioid withdrawal and reverse overdose — were never restricted by any of this. They remain legal, prescribable, and in most states available without a prescription at the pharmacy counter. A bridge clinic will treat kratom, tianeptine, and 7-OH withdrawal the same way it treats any other opioid withdrawal, because clinically, it is one — that door hasn’t closed just because the gas-station shelf emptied out.

Ben Taylor made it through to the other side of that withdrawal and now spends his workday telling other people it’s survivable. The bans didn’t do that for him. Treatment did. The gap this ban exposed isn’t a scheduling gap — it’s the distance between the day a supply disappears and the day someone dependent on it can actually reach a clinician, and right now that distance is being measured in overdoses.